Opinion|Videos|June 4, 2024
Reflex Testing for Patients with Suspected Lung Cancer
Key opinion leaders highlight findings from a University of Pennsylvania study demonstrating that implementing reflex next-generation sequencing testing can reduce time-to-treatment from 19 days to 10 days, potentially leading to improved overall patient outcomes and survival rates in non-small cell lung cancer.
Advertisement
Episodes in this series
- Please discuss the rationale for conducting liquid-based testing at the time of diagnostic biopsy in patients with suspected advanced NSCLC vs a reflex testing approach. (
Thompson JC, et al. JTO Clin Res Rep, 2022 )
- What do prospective data demonstrate?
- Please comment on the goal of having test results available upon the first patient interaction.
- Please discuss data surrounding the impact of concurrent liquid and tissue-based testing on the quality of care in advanced NSCLC. (
Maity, et al. JCO Oncology Practice, 2023 )- What impact does concurrent testing have on time to diagnosis, the need for repeat tissue biopsy, detection of actionable biomarkers?
- What are some limitations associated with tissue-based testing?
- What do data demonstrate regarding the availability of molecular testing results and overall survival of patients with advanced NSCLC? (
Aggarwal, et al. JCO Prec Oncol, 2023 )
Advertisement
Related to this article
TRE-515 earned fast track status in combination with KRAS inhibitors for G12C-mutated NSCLC after anti–PD-(L)1 therapy and platinum-based chemotherapy.
An NDA for zipalertinib in EGFR exon 20 insertion–positive NSCLC is being supported by phase 3 REZILIENT3 data.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in September 2026.
Estelamari Rodriguez, MD, MPH, discusses the rationale, design, and practice implications of the phase 3 RELATIVITY-1093 trial in nonsquamous NSCLC.
Plinabulin plus docetaxel received fast track designation for pretreated nonsquamous NSCLC without actionable genomic alterations.
Faculty convened at an OncLive Scientific Interchange and Workshop to discuss individualized treatment and strategic sequencing in HER2-mutated NSCLC.
An NDA seeks FDA approval of savolitinib plus osimertinib for EGFR-mutated NSCLC with MET overexpression or amplification after EGFR TKI therapy.
Advertisement
Advertisement
Trending on OncLive
1
Revisit Every OncLive On Air Episode From September 2026
2
Oral Azacitidine and Cedazuridine Meets Primary Pharmacokinetic End Point in MDS and CMML
3
Optune Pax Is Approved in Japan for Unresectable Locally Advanced Pancreatic Cancer
4
UTRxMYCN M1-14 Nets FDA Dual Designations in Soft Tissue Sarcoma
5